Back to Browse Journals » Patient Preference and Adherence » Volume 2

Clopidogrel-taking behavior by drug-eluting stent patients: Discontinuers versus continuers

Authors Carole Decker, Linda Garavalia, Brian Garavalia, John A Spertus

Published Date June 2008 Volume 2008:2 Pages 167—175

DOI http://dx.doi.org/10.2147/PPA.S3443

Published 3 June 2008

Carole Decker1, Linda Garavalia2, Brian Garavalia1, John A Spertus1

1Mid America Heart Institute, Saint Luke’s Hospital, Kansas City, MO, USA; 2Department of Psychology, University of Missouri, Kansas City, MO, USA

Background: Each day, patients make choices whether or not to take their prescribed medications. Previous research has shown that 1 in 7 myocardial infarction (MI) patients discontinued thienopyridines within 1 month of receiving a drug-eluting stent (DES) with serious consequences. This qualitative research study explored in depth the clopidogrel-taking behavior among DES-treated patients who quit taking clopidogrel 1 month after treatment and those who continued therapy.

Methods: Sequential patients from a prospective MI registry who reported discontinuing clopidogrel within 30 days of DES treatment (N = 11) were matched with continuers (N = 11). Both groups underwent detailed qualitative phone interviews. Coding and thematic representation using directed qualitative content analysis by 3 PhD researchers was done.

Results: Patients were 41–77 years old and the majority was Caucasian and male. Multiple barriers were described by discontinuers that were not reported by continuers. The most frequently cited barrier was misunderstanding the intended duration of treatment. Discontinuers also described system weaknesses that contributed to early discontinuance such as gaps in the transition to primary care.

Conclusions: While premature discontinuation of a prescribed therapy is viewed by clinicians as a willful disregard for medical advice, early stopping of clopidogrel is influenced greatly by processes of care and system issues.

Keywords: medication discontinuance, drug-eluting stent post-care, myocardial infarction

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians

Decker C, Garavalia L, Garavalia B, Simon T, Loeb M, Spertus J, Daniel WC

Journal of Multidisciplinary Healthcare 2012, 5:129-135

Published Date: 13 June 2012

Readers of this article also read:

Inflammatory mediators: Parallels between cancer biology and stem cell therapy

A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar

Journal of Inflammation Research 2009, 2:13-19

Published Date: 4 February 2009

Imaging of peripheral vascular disease

Mo Al-Qaisi, David M Nott, David H King, Sam Kaddoura, Mo Hamady

Reports in Medical Imaging 2009, 2:25-34

Published Date: 27 March 2009

Nanomedicine for the reduction of the thrombogenicity of stent coatings

Varvara C Karagkiozaki, Stergios D Logothetidis, Spyridon N Kassavetis, et al

International Journal of Nanomedicine 2010, 5:239-248

Published Date: 29 March 2010

New stent design for use in small coronary arteries during percutaneous coronary intervention

Juan F Granada, Barbara A Huibregtse, Keith D Dawkins

Medical Devices: Evidence and Research 2010, 3:57-66

Published Date: 19 October 2010

Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor

Mannu P, Rinaldi S, Fontani V, Castagna A

Neuropsychiatric Disease and Treatment 2011, 7:373-379

Published Date: 15 June 2011

Long-term effectiveness and safety of sirolimus drug-eluting stents

Bikkina M, Koneru J

Medical Devices: Evidence and Research 2011, 4:117-124

Published Date: 17 August 2011

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects

Margari F, Sicolo M, Spinelli L, Mastroianni F, Pastore A, Craig F, Petruzzelli MG

Neuropsychiatric Disease and Treatment 2012, 8:347-353

Published Date: 1 August 2012

Novel nanostructured biomaterials: implications for coronary stent thrombosis

Karagkiozaki V, Karagiannidis PG, Kalfagiannis N, Kavatzikidou P, Patsalas P, Georgiou D, Logothetidis S

International Journal of Nanomedicine 2012, 7:6063-6076

Published Date: 17 December 2012